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(PART A)STATE-OF-THE-ART PAPERS STATE-OF-THE-ART PAPERSStrain to Detect Chemotherapy Cardiotoxicity 2751
Paaladinesh Thavendiranathan, Frédéric Poulin, Ki-Dong Lim, Juan Carlos Plana, Anna Woo,
Thomas H. Marwick
Thavendiranathan and colleagues performed a systematic review of the literature regarding
the use of echocardiographically derived myocardial deformation parameters to detect
myocardial injury (cardiotoxicity) in patients who were receiving cancer therapy. These
studies show that alterations of myocardial deformation precede changes in left ventricular
ejection fraction (LVEF). A 10% to 15% early reduction in global longitudinal strain by
speckle tracking echocardiography during therapy appears to be the most useful parameter for
the prediction of cardiotoxicity. Furthermore, in late survivors of cancer, measures of global
radial and circumferential strain are consistently abnormal, even in the context of normal
LVEF.STATE-OF-THE-ART PAPERSECMO in Cardiopulmonary Disease 2769Darryl Abrams, Alain Combes, Daniel Brodie
The use of extracorporeal membrane oxygenation (ECMO) for both respiratory and cardiac
failure in adults is evolving rapidly. Expanding indications and novel strategies are being
employed, yet clinical data are sparse. Abrams and colleagues review cannulation strategies,
indications, and evidence for ECMO in respiratory and cardiac failure in adults.(continued on page A-31)
JULY 1, 2014 (continued)VIEWPOINTS AND
COMMENTARYA-31VIEWPOINTS AND COMMENTARYCuring Atherosclerosis 2779
Jennifer G. Robinson, Samuel S. Gidding
Robinson and Gidding argue that a new approach to atherosclerotic cardiovascular disease
prevention is needed. They propose a paradigm focused on curing atherosclerosis early in the
course of the disease through atherosclerosis regression and normalization of vessel function
with aggressive low-density lipoprotein cholesterol (LDL-C) lowering. Proof-of-concept
studies are needed to: 1) determine the optimal age and/or degree of atherosclerosis for
intervention and LDL-C–lowering therapy; 2) determine the intensity and duration of
therapy for inducing atherosclerosis regression; and 3) document the normalization of
vascular function. An accompanying commentary by Daniels commends the authors for a
piece that provokes thought and provides hypotheses to be tested, but warns against changes
to current clinical practice.
Commentary: Stephen R. Daniels, p. 2876VIEWPOINTS AND COMMENTARYAnalysis of Risk Assessment Guidelines 2789
Nivee P. Amin, Seth S. Martin, Michael J. Blaha, Khurram Nasir, Roger S. Blumenthal, Erin D. Michos
The 2013 American College of Cardiology/American Heart Association Guidelines for
Assessing Cardiovascular Risk makes signiﬁcant progress compared with prior cardiovascular
risk assessment systems. Its new focus on total atherosclerotic cardiovascular diseases now
includes stroke. There are separate equations to facilitate calculation of risk in non-Hispanic
white and black individuals and in women. Despite this important progress, using the new
risk calculators may lead to inaccurate assessment of atherosclerotic cardiovascular risk. Amin
and colleagues propose that the new guidelines should have incorporated guidance on other
methods to further reﬁne an individual patient’s risk.(continued on page A-32)
JULY 1, 2014 (continued) A-32CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGYCaval-Aortic Access for TAVR 2795Adam B. Greenbaum, William W. O’Neill, Gaetano Paone, Mayra E. Guerrero, Janet F. Wyman,
R. Lebron Cooper, Robert J. Lederman
Greenbaum and colleagues describe the use of caval-aortic access to enable transcatheter
aortic valve replacement (TAVR) in 19 patients who lacked other access options. Caval-aortic
access refers to percutaneous entry into the abdominal aorta from the femoral vein through
the adjoining inferior vena cava. Caval-aortic access and tract closure was successful in all
19 patients; TAVR was successful in 17 patients. A total of 6 patients experienced VARC-2
(Valve Academic Research Consortium-2) major vascular complications, 2 (11%) of whom
required intervention. There were no deaths attributable to caval-aortic access. Through a
median 111 days (range 39 to 229 days) of follow-up, there were no post-discharge
complications related to tract creation or closure. Percutaneous transcaval venous access to the
aorta may provide a new access strategy for TAVR and other applications requiring large
transcatheter implants.INTERVENTIONAL CARDIOLOGYThe HOST–ASSURE Trial 2805
Kyung Woo Park, Si-Hyuck Kang, Hyun-Jae Kang, Bon-Kwon Koo, Byoung-Eun Park, Kwang Soo Cha,
Jay Young Rhew, Hui-Kyoung Jeon, Eun-Seok Shin, Ju Hyeon Oh, Myung-Ho Jeong, Sanghyun Kim,
Kyung-Kuk Hwang, Jung-Han Yoon, Sung Yun Lee, Tae-Ho Park, Keon Woong Moon,
Hyuck-Moon Kwon, Seung-Ho Hur, Jae-Kean Ryu, Bong-Ryul Lee, Yong Whi Park, In-Ho Chae,
Hyo-Soo Kim, on behalf of the HOST–ASSURE Investigators
Park and colleagues randomly assigned 3,755 all-comers undergoing percutaneous coronary
intervention (PCI) to a platinum chromium-based everolimus-eluting stent (PtCr-EES) or a
cobalt chromium-based zotarolimus-eluting stent (CoCr-ZES) in the HOST-ASSURE
(Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis–Safety &
Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen) trial. At 1 year post-PCI,
target lesion failure (TLF) occurred in 2.9% and 2.9% of patients in the PtCr-EES and
CoCr-ZES groups, respectively. There were no signiﬁcant differences in the individual
components of TLF. This was one of the largest direct stent comparison studies ever
performed and shows noninferiority of PtCr-EES against CoCr-ZES.(continued on page A-33)
JULY 1, 2014 (continued) A-33HEART FAILURECAD Impacts Outcomes in HFpEF 2817
Seok-Jae Hwang, Vojtech Melenovsky, Barry A. Borlaug
Hwang and colleagues investigated the prognostic impact of coronary artery disease (CAD)
in 376 patients with heart failure with preserved ejection fraction (HFpEF) who underwent
coronary angiography. Symptoms of angina and heart failure were similar in patients with
and without CAD. HFpEF patients with CAD displayed greater deterioration in ejection
fraction (EF) and increased mortality. Complete revascularization was associated with less
deterioration in EF and lower mortality compared with patients that were not completely
revascularized. Complete revascularization may be optimal for patients with CAD and
HFpEF.
Editorial Comment: Barry Greenberg, p. 2828HEART FAILUREPeripartum Cardiomyopathy and ICD Use 2831
Jayasree Pillarisetti, Ashok Kondur, Anas Alani, Madhu Reddy, Madhuri Reddy, James Vacek,
Carl P. Weiner, Edward Ellerbeck, Theodore Schreiber, Dhanunjaya Lakkireddy
Pillarisetti and colleagues performed a long-term retrospective study to identify the predictors
of left ventricular (LV) recovery in patients with peripartum cardiomyopathy (PPCM). The
total sample comprised 100 patients, of which 42% showed improvement in LV ejection
fraction (EF) over a mean duration of 33 months. Post-partum diagnosis and Caucasian/
Hispanic race were predictors of subsequent LVEF improvement. Only 7 of the 58 patients
(12%) who did not show improvement in their EF had implantable cardioverter-deﬁbrillators
(ICDs) implanted. There were 11 deaths, with a trend toward higher mortality in those
patients whose LV function did not improve (15% vs. 5%, p ¼ 0.1). These results show that
slightly more than one-half of patients with PPCM will not recover LV function and may be
candidates for ICD therapy.(continued on page A-34)
JULY 1, 2014 (continued) A-34HEART RHYTHM DISORDERSAF Classiﬁcation and Temporal Persistence 2840
Efstratios I. Charitos, Helmut Pürerfellner, Taya V. Glotzer, Paul D. Ziegler
Charitos and colleagues aimed to identify how accurately the current clinical classiﬁcations of
paroxysmal, persistent, and permanent atrial ﬁbrillation (AF) reﬂect temporal persistence as
detected by cardiac rhythm devices. Patients were classiﬁed by physicians at baseline in
accordance with current guidelines. Agreement between the clinical AF classiﬁcation and the
objective device-derived assessments of AF temporal persistence was poor. The authors
conclude that the currently used clinical AF classiﬁcations poorly reﬂect AF temporal
persistence.
Editorial Comment: Suneet Mittal, p. 2849HEART VALVE DISEASEThe Epidemiology of Aortic Sclerosis 2852
Sean Coffey, Brian Cox, Michael J. A. Williams
Aortic sclerosis (ASc), a thickening or calciﬁcation of the aortic valve without signiﬁcant
obstruction to blood ﬂow, is a common ﬁnding on cardiac imaging. Coffey and colleagues
comprehensively reviewed the epidemiology of ASc and its association with cardiovascular
events. A total of 22 studies were identiﬁed from the systematic review. The prevalence of
ASc increased in proportion to the average age of study participants, ranging from 9% in a
study with a mean age of 54 years, to 42% in a study with a mean age of 81 years. Per year,
1.8% to 1.9% of participants with ASc progressed to clinical aortic stenosis. Patients with
ASc were at higher risk for coronary events, stroke, cardiovascular mortality, and all-cause
mortality. ASc is a common ﬁnding in elderly subjects, and despite low rates of progression to
aortic stenosis, it identiﬁes subjects at increased risk for cardiovascular events.PRE-CLINICAL RESEARCH PRE-CLINICAL RESEARCHPlasminogen and Stem Cell–Mediated Cardiac Repair 2862
Yanqing Gong, Yujing Zhao, Ying Li, Yi Fan, Jane Hoover-Plow
Gong and colleagues performed a series of studies in mouse models to investigate the role of
plasminogen (Plg) in stem cell–mediated cardiac repair and regeneration. Myocardial
infarction (MI) was induced in Plg-deﬁcient (Plg/) and wild-type (Plg+/+) mice by ligation
of the left anterior descending coronary artery. Plg deﬁciency markedly inhibited stem cell
homing and cardiac repair. These ﬁndings have identiﬁed a novel role of Plg in stem
cell–mediated cardiac repair after MI and suggest that augmenting Plg may improve the
results for stem cell–mediated cardiac repair after MI.
Editorial Comment: Douglas W. Losordo, Douglas E. Vaughan, p. 2873
